Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy ... Right now, we’re issuing ...

So we're quite confident both in the demand in the market and also our ability to supply and compete in that market." People taking Wegovy start off on the lowest dose – or the starter dose ...

Sales of weight loss drug Wegovy more than doubled in the final ... Lars Fruergaard Jorgensen, president and chief executive, said: “We are pleased with the performance in 2024, where 26% ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday ... propelled by its popular injections. "We are pleased with ...

In addition to Wegovy, incretin mimetics FDA-approved for ... teased upcoming bipartisan legislation relevant to the ad. “We recognize the important roles that pharmaceutical compounding and ...